Using light to diagnose kidney disease
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with one of these kidney diseases: IgA nephropathy, membranous nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis (confirmed by a kidney biopsy).
- You have not taken hormone therapy or immunosuppressant drugs before your kidney biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study tests a new medicine, RG002C0106, to see how it is processed in people with normal or mildly to moderately reduced kidney function. It helps researchers understand how kidney function affects the drug, which is important for future dosing recommendations.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
This study uses special kidney imaging to look for patterns that can predict how diabetic kidney disease may progress. It may help researchers find better ways to identify people at higher risk using noninvasive (and possibly biopsy-related) tests.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.